FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361955641> ?p ?o ?g. }

• W4361955641 abstract "<div>AbstractPurpose:<p>In metastatic colorectal cancer (mCRC), <i>HER2</i> (<i>ERBB2</i>) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combined with cetuximab, in patients with progressive disease (PD) on anti-EGFR treatment.</p>Patients and Methods:<p>Twenty-one patients with quadruple-wild-type, refractory mCRC enrolled in this 3+3 phase Ib study. Standard dosage cetuximab was administered with neratinib at 120 mg, 160 mg, 200 mg, and 240 mg/day orally in 28-day cycles. Samples were collected for molecular and pharmacokinetic studies.</p>Results:<p>Sixteen patients were evaluable for dose-limiting toxicity (DLT). 240 mg was determined to be the RP2D wherein a single DLT occurred (1/7 patients). Treatment-related DLTs were not seen at lower doses. Best response was stable disease (SD) in 7 of 16 (44%) patients. <i>HER2</i> amplification (chromogenic <i>in situ</i> IHC) was detected in 2 of 21 (9.5%) treatment-naïve tumors and 4 of 16 (25%) biopsies upon trial enrollment (post-anti-EGFR treatment and progression). Compared with matched enrollment biopsies, 6 of 8 (75%) blood samples showed concordance for <i>HER2</i> CNV in circulating cell-free DNA. Five SD patients had <i>HER2</i> amplification in either treatment-naïve or enrollment biopsies. Examination of gene-expression, total protein, and protein phosphorylation levels showed relative upregulation of ≥2 members of the HER-family receptors or ligands upon enrollment versus matched treatment-naïve samples.</p>Conclusions:<p>The RP2D of neratinib in this combination was 240 mg/day, which was well tolerated with low incidence of G3 AEs. There were no objective responses; SD was seen at all neratinib doses. <i>HER2</i> amplification, detectable in both tissue and blood, was more frequent post-anti-EGFR therapy.</p></div>" @default.
• W4361955641 created "2023-04-05" @default.
• W4361955641 creator A5009193095 @default.
• W4361955641 creator A5009480096 @default.
• W4361955641 creator A5013172168 @default.
• W4361955641 creator A5018863416 @default.
• W4361955641 creator A5020154592 @default.
• W4361955641 creator A5021672645 @default.
• W4361955641 creator A5028047400 @default.
• W4361955641 creator A5030889960 @default.
• W4361955641 creator A5037503098 @default.
• W4361955641 creator A5040410256 @default.
• W4361955641 creator A5047818279 @default.
• W4361955641 creator A5049175137 @default.
• W4361955641 creator A5055013606 @default.
• W4361955641 creator A5060040445 @default.
• W4361955641 creator A5065332366 @default.
• W4361955641 creator A5069843364 @default.
• W4361955641 creator A5070667099 @default.
• W4361955641 creator A5079315515 @default.
• W4361955641 creator A5083386276 @default.
• W4361955641 creator A5084193961 @default.
• W4361955641 creator A5091299001 @default.
• W4361955641 date "2023-03-31" @default.
• W4361955641 modified "2023-10-16" @default.
• W4361955641 title "Data from Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study" @default.
• W4361955641 doi "https://doi.org/10.1158/1078-0432.c.6530607.v1" @default.
• W4361955641 hasPublicationYear "2023" @default.
• W4361955641 type Work @default.
• W4361955641 citedByCount "0" @default.
• W4361955641 crossrefType "posted-content" @default.
• W4361955641 hasAuthorship W4361955641A5009193095 @default.
• W4361955641 hasAuthorship W4361955641A5009480096 @default.
• W4361955641 hasAuthorship W4361955641A5013172168 @default.
• W4361955641 hasAuthorship W4361955641A5018863416 @default.
• W4361955641 hasAuthorship W4361955641A5020154592 @default.
• W4361955641 hasAuthorship W4361955641A5021672645 @default.
• W4361955641 hasAuthorship W4361955641A5028047400 @default.
• W4361955641 hasAuthorship W4361955641A5030889960 @default.
• W4361955641 hasAuthorship W4361955641A5037503098 @default.
• W4361955641 hasAuthorship W4361955641A5040410256 @default.
• W4361955641 hasAuthorship W4361955641A5047818279 @default.
• W4361955641 hasAuthorship W4361955641A5049175137 @default.
• W4361955641 hasAuthorship W4361955641A5055013606 @default.
• W4361955641 hasAuthorship W4361955641A5060040445 @default.
• W4361955641 hasAuthorship W4361955641A5065332366 @default.
• W4361955641 hasAuthorship W4361955641A5069843364 @default.
• W4361955641 hasAuthorship W4361955641A5070667099 @default.
• W4361955641 hasAuthorship W4361955641A5079315515 @default.
• W4361955641 hasAuthorship W4361955641A5083386276 @default.
• W4361955641 hasAuthorship W4361955641A5084193961 @default.
• W4361955641 hasAuthorship W4361955641A5091299001 @default.
• W4361955641 hasBestOaLocation W43619556412 @default.
• W4361955641 hasConcept C121608353 @default.
• W4361955641 hasConcept C126322002 @default.
• W4361955641 hasConcept C143998085 @default.
• W4361955641 hasConcept C2778332735 @default.
• W4361955641 hasConcept C2779413316 @default.
• W4361955641 hasConcept C2779786085 @default.
• W4361955641 hasConcept C2779998722 @default.
• W4361955641 hasConcept C2781187634 @default.
• W4361955641 hasConcept C526805850 @default.
• W4361955641 hasConcept C530470458 @default.
• W4361955641 hasConcept C71924100 @default.
• W4361955641 hasConcept C90924648 @default.
• W4361955641 hasConceptScore W4361955641C121608353 @default.
• W4361955641 hasConceptScore W4361955641C126322002 @default.
• W4361955641 hasConceptScore W4361955641C143998085 @default.
• W4361955641 hasConceptScore W4361955641C2778332735 @default.
• W4361955641 hasConceptScore W4361955641C2779413316 @default.
• W4361955641 hasConceptScore W4361955641C2779786085 @default.
• W4361955641 hasConceptScore W4361955641C2779998722 @default.
• W4361955641 hasConceptScore W4361955641C2781187634 @default.
• W4361955641 hasConceptScore W4361955641C526805850 @default.
• W4361955641 hasConceptScore W4361955641C530470458 @default.
• W4361955641 hasConceptScore W4361955641C71924100 @default.
• W4361955641 hasConceptScore W4361955641C90924648 @default.
• W4361955641 hasLocation W43619556411 @default.
• W4361955641 hasLocation W43619556412 @default.
• W4361955641 hasOpenAccess W4361955641 @default.
• W4361955641 hasPrimaryLocation W43619556411 @default.
• W4361955641 hasRelatedWork W1541436518 @default.
• W4361955641 hasRelatedWork W1980946342 @default.
• W4361955641 hasRelatedWork W2010163599 @default.
• W4361955641 hasRelatedWork W2019279330 @default.
• W4361955641 hasRelatedWork W2034550393 @default.
• W4361955641 hasRelatedWork W2589642515 @default.
• W4361955641 hasRelatedWork W2617055067 @default.
• W4361955641 hasRelatedWork W3000288349 @default.
• W4361955641 hasRelatedWork W3094547569 @default.
• W4361955641 hasRelatedWork W3180628252 @default.
• W4361955641 isParatext "false" @default.
• W4361955641 isRetracted "false" @default.
• W4361955641 workType "article" @default.